Skip to main content

Table 2 Univariate analysis of prognostic factors of each endpoint

From: Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study

Factor

2y-OS

2y-LC

2y-PFS

%

P

%

P

%

P

Age (years)

<  66 (n = 57)

56.6

0.21

50.8

0.04

16.2

0.150

≥ 66 (n = 56)

71.3

 

69.2

 

22.5

 

Gender

Male (n = 45)

55.1

0.11

59.1

0.42

21.1

0.97

Female (n = 68)

68.2

 

60.3

 

17.8

 

Performance status

0 (n = 68)

69.2

0.49

61.6

0.97

19.1

0.93

1–2 (n = 45)

54.5

 

56.7

 

19.9

 

Primary site

Colorectum

73.5

0.49

64.1

0.79

21.9

0.96

Uterine cervix

88.4

 

60.7

 

25.8

 

Endometrium

54.4

 

59.3

 

23.3

 

Pathological type

Adenocarcinoma

66.1

0.86

59.7

0.37

19.4

0.76

Squamous cell carcinoma

67.2

 

60.4

 

23.5

 

Initial T-category

T1–2 (n = 64)

68.7

0.07

64.2

0.61

22.9

0.69

T3–4 (n = 49)

56.0

 

54.7

 

16.2

 

Initial N-category

N negative (n = 49)

66.6

0.09

64.2

0.72

23.8

0.61

N positive (n = 64)

60.2

 

56.1

 

16.6

 

Duration from initial diagnosis (months)

<  24.1 (n = 57)

60.9

0.94

63.8

0.43

20.7

0.59

≥ 24.1 (n = 56)

63.9

 

54.9

 

18.0

 

DFI (months)

<  8.5 (n = 57)

53.4

0.04

52.4

0.30

13.5

0.01

≥ 8.5 (n = 56)

72.5

 

66.0

 

24.9

 

Radiation therapy method

3DCRT (n = 47)

56.1

0.49

50.9

0.01

26.0

0.82

IMRT&SBRT (n = 66)

67.9

 

64.9

 

14.5

 

Extra-regional LN for primary site

no (n = 65)

65.5

0.07

60.6

0.92

21.9

0.45

yes (n = 48)

59.7

 

57.7

 

15.3

 

Number of LN

1 (n = 61)

73.3

0.01

70.4

0.01

25.1

0.08

2–5 (n = 52)

51.3

 

47.8

 

12.9

 

LN size (cm)

<  2 (n = 62)

71.6

0.17

66.0

0.06

18.1

0.68

≥ 2 (n = 51)

52.0

 

52.4

 

20.7

 

Prophylactic nodal irradiation

no (n = 69)

63.7

0.69

63.3

0.41

15.8

0.80

yes (n = 44)

61.4

 

54.9

 

28.2

 

Concurrent chemotherapy

no (n = 80)

63.5

0.92

58.8

0.69

11.0

0.20

yes (n = 33)

59.5

 

60.8

 

36.1

 

EQD2 (Gy)

<  60 (n = 58)

52.7

0.08

45.2

< 0.001

21.1

0.87

≥ 60 (n = 55)

74.8

 

74.9

 

17.5

 
  1. n number of patients, OS overall survival rate, LC local control rate, PFS progression-free survival rate, DFI disease-free interval, 3DCRT 3-dimentional conformal radiation therapy, IMRT intensity-modulated radiation therapy, SBRT Stereotactic Body Radiation Therapy, LN lymph node, EQD2 equivalent dose in 2 Gy fraction